GB1349158A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- GB1349158A GB1349158A GB1349158DA GB1349158A GB 1349158 A GB1349158 A GB 1349158A GB 1349158D A GB1349158D A GB 1349158DA GB 1349158 A GB1349158 A GB 1349158A
- Authority
- GB
- United Kingdom
- Prior art keywords
- carrier
- palmitate
- stearate
- corticosteroid
- oleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- HNXBFGYKBOUTRR-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC HNXBFGYKBOUTRR-UHFFFAOYSA-N 0.000 abstract 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 abstract 1
- CBACFHTXHGHTMH-UHFFFAOYSA-N 2-piperidin-1-ylethyl 2-phenyl-2-piperidin-1-ylacetate;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1C(C=1C=CC=CC=1)C(=O)OCCN1CCCCC1 CBACFHTXHGHTMH-UHFFFAOYSA-N 0.000 abstract 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 239000005995 Aluminium silicate Substances 0.000 abstract 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 239000004166 Lanolin Substances 0.000 abstract 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 abstract 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 abstract 1
- 229910004298 SiO 2 Inorganic materials 0.000 abstract 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 229910010413 TiO 2 Inorganic materials 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000012211 aluminium silicate Nutrition 0.000 abstract 1
- 239000000440 bentonite Substances 0.000 abstract 1
- 229910000278 bentonite Inorganic materials 0.000 abstract 1
- 235000012216 bentonite Nutrition 0.000 abstract 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 abstract 1
- XXCBNHDMGIZPQF-UHFFFAOYSA-L bismuth(2+);5-carboxy-3-hydroxybenzene-1,2-diolate;hydrate Chemical compound O.OC1=CC(C(=O)O)=CC2=C1O[Bi]O2 XXCBNHDMGIZPQF-UHFFFAOYSA-L 0.000 abstract 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 abstract 1
- 229960005091 chloramphenicol Drugs 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 abstract 1
- 229960003662 desonide Drugs 0.000 abstract 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 abstract 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 abstract 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 abstract 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 abstract 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 229940042902 flumethasone pivalate Drugs 0.000 abstract 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 abstract 1
- 229960001347 fluocinolone acetonide Drugs 0.000 abstract 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 abstract 1
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 abstract 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 abstract 1
- 208000014617 hemorrhoid Diseases 0.000 abstract 1
- 229960001067 hydrocortisone acetate Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229940039717 lanolin Drugs 0.000 abstract 1
- 235000019388 lanolin Nutrition 0.000 abstract 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 abstract 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229940099273 magnesium trisilicate Drugs 0.000 abstract 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 abstract 1
- 235000019793 magnesium trisilicate Nutrition 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 abstract 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940049964 oleate Drugs 0.000 abstract 1
- 229940055577 oleyl alcohol Drugs 0.000 abstract 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 229960000249 pregnenolone Drugs 0.000 abstract 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229950006451 sorbitan laurate Drugs 0.000 abstract 1
- 229950004959 sorbitan oleate Drugs 0.000 abstract 1
- 229950003429 sorbitan palmitate Drugs 0.000 abstract 1
- 229950011392 sorbitan stearate Drugs 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 229960004274 stearic acid Drugs 0.000 abstract 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229920001059 synthetic polymer Polymers 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 239000002278 tabletting lubricant Substances 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 229960002117 triamcinolone acetonide Drugs 0.000 abstract 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
1349158 Corticosteroid preparations ETABS ARPIC SA 17 Nov 1972 [19 Nov 1971] 53945/ 71 Heading A5B Pharmaceutical compositions suitable for topical, oral and rectal administration comprise carrier particles coated with a corticosteroid. The carrier may be talc, colloidal SiO 2 , Al 2 O 3 , bentonite, kaolin, magnesium trisilicate, lactose corn starch, microspheres of a synthetic polymer, a metal stearate, cellulose, a cellulose derivative, ZnO, TiO 2 or a pharmacologically active ingredient, e.g. bismuth oxyiodide, oxychloride, subnitrate, subcarbonate or subgallate, a sulphonamide, neomycin sulphate, tetracycline hydrochloride, chloramphenicol, amphoteracin B or nistatine. The steroid may be prednacinolone, triamcinolone acetonide, fluocinolone acetonide, flumethasone pivalate, hydrocortisone acetate, triamcinolone, prednisolone, pregnenolone or betamethasone. The coated particles may also include a surface active agent, e.g. glycerol monostearate or palmitate or ethylene oxide adducts of lauryl, cetyl, stearyl or oleyl alcohol, stearic acid, sorbitan stearate, laurate, palmitate or oleate, glycerol stearate laurate, palmitate or oleate or lanolin. They may be prepared by dissolving the corticosteroid in an organic solvent or an organic solvent / water emulsion, suspending the carrier in this solution and spray drying the product. The coated particles may be mixed with other ingredients e.g. other active ingredients such as lidocaine hydrochloride, a tabletting lubricant, e.g. magnesium stearate and other carrier and excipients. The product may be put up as powder, tablets, gelatin capsules or suppositories, which may be used in treating haemorrhoids.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5394571 | 1971-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1349158A true GB1349158A (en) | 1974-03-27 |
Family
ID=10469486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1349158D Expired GB1349158A (en) | 1971-11-19 | 1971-11-19 | Pharmaceutical compositions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1349158A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987000428A1 (en) * | 1985-07-24 | 1987-01-29 | Pyare Seth | Oxazepam containing pharmaceutical composition |
| EP0468121A1 (en) * | 1989-07-13 | 1992-01-29 | Philippe Perovitch | Process for the galenical preparation of a therapeutic composition, in particular based on aspirin |
| FR2721212A1 (en) * | 1994-06-17 | 1995-12-22 | Pf Medicament | New dermo-pharmaceutical compsn. |
| US5683721A (en) * | 1990-07-26 | 1997-11-04 | Perovitch; Philippe | Galenic preparation of therapeutic composition comprising aspirin |
| WO2008001140A3 (en) * | 2006-06-28 | 2008-06-26 | Univ Sunderland | Pellet formulation comprising colloidal silicon dioxide |
-
1971
- 1971-11-19 GB GB1349158D patent/GB1349158A/en not_active Expired
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987000428A1 (en) * | 1985-07-24 | 1987-01-29 | Pyare Seth | Oxazepam containing pharmaceutical composition |
| EP0468121A1 (en) * | 1989-07-13 | 1992-01-29 | Philippe Perovitch | Process for the galenical preparation of a therapeutic composition, in particular based on aspirin |
| WO1992001444A1 (en) * | 1989-07-13 | 1992-02-06 | Philippe Perovitch | Galenical preparation method for preparing a therapeutical composition particularly based on aspirin |
| US5629022A (en) * | 1989-07-13 | 1997-05-13 | Perovitch; Philippe | Method for galenically preparing a therapeutic composition based on aspirin |
| US5683721A (en) * | 1990-07-26 | 1997-11-04 | Perovitch; Philippe | Galenic preparation of therapeutic composition comprising aspirin |
| FR2721212A1 (en) * | 1994-06-17 | 1995-12-22 | Pf Medicament | New dermo-pharmaceutical compsn. |
| WO2008001140A3 (en) * | 2006-06-28 | 2008-06-26 | Univ Sunderland | Pellet formulation comprising colloidal silicon dioxide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0037740B1 (en) | Solid microdose drug preparation | |
| US3344029A (en) | Sustained release composition | |
| CA2227887C (en) | Pharmaceutical compositions of conjugated estrogens and methods for their use | |
| DE2432925C3 (en) | Film-shaped medicinal products | |
| GB1446626A (en) | Composition for sustained release of a medicament and method of using same | |
| DE69322396T2 (en) | Pharmaceutical granules containing steroids | |
| DE69404116T2 (en) | Pharmaceutical dosage unit coated with sugar | |
| SI9012150A (en) | Oral formulation for the treatment of infectious intestinal diseases | |
| CH625704A5 (en) | Pharmaceutical composition in sheet form | |
| GB1351409A (en) | Sustained release pharmaceutical compositions for topical appli cation | |
| MX9303604A (en) | PROCEDURE FOR OBTAINING SOLID RETARDING PHARMACEUTICAL FORMS. | |
| DE2309202A1 (en) | MEDICINAL FORMS WITH MICRO-ENCAPSULATED MEDICINAL ACTIVE | |
| CA2064150A1 (en) | Sustained release pharmaceutical preparation and process for preparing the same | |
| GB1349158A (en) | Pharmaceutical compositions | |
| DE1767326A1 (en) | Film-forming ointments | |
| Grupe | Chlorambucil in steroid-dependent nephrotic syndrome | |
| DE69108007T2 (en) | METHOD FOR PRODUCING AN ACTIVE SUBSTANCE SENSITIVE TO HEAT, LIGHT AND MOISTURE, WITH A TABLET OR DRAGED COMPOSITION CONTAINING CRYSTALLINE STRUCTURE. | |
| IE35018B1 (en) | Therapeutic agent | |
| JP2532224B2 (en) | Nicorandil tablet manufacturing method | |
| US2782975A (en) | Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing | |
| Hansen et al. | Variable efficacy of glucocorticoids in congenital adrenal hyperplasia | |
| Goldenberg et al. | Protective effect of Pepto-Bismol liquid on the gastric mucosa of rats | |
| US2888382A (en) | Therapeutic composition and process | |
| DE69702985T2 (en) | Dosage forms containing steroid with a steroid-tight envelope | |
| GB1529607A (en) | Medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PLNP | Patent lapsed through nonpayment of renewal fees |